{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "24617414",
  "DateCompleted": {
    "Year": "2014",
    "Month": "11",
    "Day": "25"
  },
  "DateRevised": {
    "Year": "2020",
    "Month": "12",
    "Day": "09"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2014",
        "Month": "03",
        "Day": "11"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1586/14787210.2014.894883"
    ],
    "Journal": {
      "ISSN": "1744-8336",
      "JournalIssue": {
        "Volume": "12",
        "Issue": "5",
        "PubDate": {
          "Year": "2014",
          "Month": "May"
        }
      },
      "Title": "Expert review of anti-infective therapy",
      "ISOAbbreviation": "Expert Rev Anti Infect Ther"
    },
    "ArticleTitle": "Pneumocystis and Pneumocystosis: first meeting of experts from Latin-American and Portuguese-speaking countries - a mini-review.",
    "Pagination": {
      "StartPage": "545",
      "EndPage": "548",
      "MedlinePgn": "545-8"
    },
    "Abstract": {
      "AbstractText": [
        "The Pneumocystis and Pneumocystosis: first meeting of experts from Latin-American and Portuguese-speaking countries was held in Lisbon, Portugal, on 24-26 October 2013. A total of 20 speakers from Latin America, Africa and Europe participated in the meeting. The epidemiological studies presented in this meeting begin to change the misconception that since the AIDS epidemic, Pneumocystis pneumonia (PcP) has become an infrequent disease, showing that today PcP remains a major opportunistic infection in HIV-infected patients in both developed and developing countries and an emerging problem in immunocompromised patients without HIV infection worldwide. PcP management remains a challenge. Right now, the combination of caspofungin and trimethoprim-sulfamethoxazole (TMP-SMX) is a promising therapeutic approach that needs to be assessed in controlled clinical trials."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Grupo de Protozo\u00e1rios Oportunistas/VIH e Outros Protozo\u00e1rios, Unidade de Parasitologia M\u00e9dica, Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa, Lisbon, Portugal."
          }
        ],
        "LastName": "Esteves",
        "ForeName": "Francisco",
        "Initials": "F"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Medrano",
        "ForeName": "Francisco J",
        "Initials": "FJ"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "de Armas",
        "ForeName": "Yaxsier",
        "Initials": "Y"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Wissmann",
        "ForeName": "Gustavo",
        "Initials": "G"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Calder\u00f3n",
        "ForeName": "Enrique J",
        "Initials": "EJ"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Matos",
        "ForeName": "Olga",
        "Initials": "O"
      }
    ],
    "PublicationTypeList": [
      "Congress"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "England",
    "MedlineTA": "Expert Rev Anti Infect Ther",
    "NlmUniqueID": "101181284",
    "ISSNLinking": "1478-7210"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Anti-Infective Agents"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Echinocandins"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Lipopeptides"
    },
    {
      "RegistryNumber": "8064-90-2",
      "NameOfSubstance": "Trimethoprim, Sulfamethoxazole Drug Combination"
    },
    {
      "RegistryNumber": "F0XDI6ZL63",
      "NameOfSubstance": "Caspofungin"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "drug therapy",
        "immunology",
        "microbiology",
        "virology"
      ],
      "DescriptorName": "AIDS-Related Opportunistic Infections"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Anti-Infective Agents"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Caspofungin"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Developed Countries"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Developing Countries"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Echinocandins"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Immunocompromised Host"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Latin America"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Lipopeptides"
    },
    {
      "QualifierName": [
        "drug effects",
        "pathogenicity",
        "physiology"
      ],
      "DescriptorName": "Pneumocystis carinii"
    },
    {
      "QualifierName": [
        "drug therapy",
        "immunology",
        "microbiology",
        "virology"
      ],
      "DescriptorName": "Pneumonia, Pneumocystis"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Trimethoprim, Sulfamethoxazole Drug Combination"
    }
  ]
}